NAS:BBIO (USA) Also Trade In: Germany
BridgeBio Pharma Inc $ 69.48 3.04 (4.58%)
Warning! GuruFocus has detected 1 Severe warning sign with BBIO. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for BridgeBio Pharma Inc () from 2019 to Jan 24 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. BridgeBio Pharma stock (BBIO) PE ratio as of Jan 24 2021 is 0. More Details
BridgeBio Pharma PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
BridgeBio Pharma PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:RARE NAS:GBT NAS:MRTX NAS:CBPO NAS:FTSV NAS:NKTR NAS:CRSP NAS:VIR NAS:IOVA NAS:ADPT OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 421 Kipling Street, Palo Alto, CA, USA, 94301
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.